Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibition

Brain, Behavior, and Immunity

Volumn 58, Issue , 2016, Pages 91-98

  Sorski, Liat ^a   Melamed, Rivka ^a   Matzner, Pini ^a   Lavon, Hagar ^a   Shaashua, Lee ^a   Rosenne, Ella ^a   Ben Eliyahu, Shamgar ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Colorectal cancer; COX 2 inhibition; CT26 colon cancer; Etodolac; Liver metastasis; Peri operative period; Propranolol; Adrenergic blocker

Indexed keywords

CATECHOLAMINE; CORTICOSTERONE; CPG OLIGODEOXYNUCLEOTIDE; ETODOLAC; GANGLIOTETRAOSYLCERAMIDE; PROPRANOLOL; PROSTAGLANDIN; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLOOXYGENASE 2 INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER CELL LINE; CANCER CONTROL; CATECHOLAMINE RELEASE; CELL STIMULATION; COLON CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CT26 CELL LINE; DRUG EFFICACY; FACTORIAL DESIGN; FEMALE; FLOW CYTOMETRY; HORMONE RESPONSE; HOST RESISTANCE; HYPOTHERMIA; LAPAROSCOPIC SURGERY; LAPAROTOMY; LIVER METASTASIS; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MALE; MENTAL STRESS; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; OPERATION DURATION; PERIOPERATIVE PERIOD; PHYSIOLOGICAL STRESS; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; TUMOR CELL INOCULATION; ANIMAL; COLON TUMOR; LIVER TUMOR; METABOLISM; MINOR SURGERY; SECONDARY; TUMOR CELL LINE;

ADRENERGIC BETA-AGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; ETODOLAC; FEMALE; KILLER CELLS, NATURAL; LAPAROTOMY; LIVER NEOPLASMS; MALE; MICE, INBRED BALB C; MINOR SURGICAL PROCEDURES; PROPRANOLOL;

EID: 84995528452     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.05.017     Document Type: Article

References (40)

1. Ben-Eliyahu, S., The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav. Immun. 17:Suppl. 1 (2003), S27–36.
2. Benish, M., Bartal, I., et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann. Surg. Oncol. 15:7 (2008), 2042–2052.
3. Biondi, A., Grosso, G., et al. Laparoscopic vs. open approach for colorectal cancer: evolution over time of minimal invasive surgery. BMC Surg., 13(Suppl. 2), 2013, S12.
4. Burkholder, B., Huang, R.Y., et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim. Biophys. Acta 1845:2 (2014), 182–201.
5. Cole, S.W., Nagaraja, A.S., et al. Sympathetic nervous system regulation of the tumour microenvironment. Nat. Rev. Cancer 15:9 (2015), 563–572.
6. Corbett, T.H., Griswold, D.P. Jr., et al. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35:9 (1975), 2434–2439.
7. Demicheli, R., Valagussa, P., et al. Does surgery modify growth kinetics of breast cancer micrometastases?. Br. J. Cancer 85:4 (2001), 490–492.
8. Elenkov, I.J., Wilder, R.L., et al. The sympathetic nerve–an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 52:4 (2000), 595–638.
9. Eschwege, P., Dumas, F., et al. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 346:8989 (1995), 1528–1530.
10. Fisher, B., Gunduz, N., et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 49:8 (1989), 1996–2001.
11. Glasner, A., Avraham, R., et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J. Immunol. 184:5 (2010), 2449–2457.
12. Goldfarb, Y., Sorski, L., et al. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann. Surg. 253:4 (2011), 798–810.
13. Horowitz, M., Neeman, E., et al. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nat. Rev. Clin. Oncol., 2015.
14. Inbar, S., Neeman, E., et al. Do stress responses promote leukemia progression? An animal study suggesting a role for epinephrine and prostaglandin-E(2) through reduced NK activity. PLoS ONE, 6(4), 2011, e19246.
15. Jayne, D.G., Thorpe, H.C., et al. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br. J. Surg. 97:11 (2010), 1638–1645.
16. Kasai, M., Yoneda, T., et al. In vivo effect of anti-asialo GM1 antibody on natural killer activity. Nature 291:5813 (1981), 334–335.
17. Lee, J.W., Shahzad, M.M., et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin. Cancer Res. 15:8 (2009), 2695–2702.
18. Melamed, R., Rosenne, E., et al. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav. Immun. 19:2 (2005), 114–126.
19. Moreno-Smith, M., Lutgendorf, S.K., et al. Impact of stress on cancer metastasis. Future Oncol. 6:12 (2010), 1863–1881.
20. Neeman, E., Ben-Eliyahu, S., Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav. Immun. 30:Suppl. (2013), S32–40.
21. Neeman, E., Zmora, O., et al. A new approach to reducing postsurgical cancer recurrence: perioperative targeting of catecholamines and prostaglandins. Clin. Cancer Res. 18:18 (2012), 4895–4902.
22. Nishikado, H., Mukai, K., et al. NK cell-depleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo. J. Immunol. 186:10 (2011), 5766–5771.
23. Rainsford, K., Advances in Anti-Rheumatic Therapy. 1996, CRC Press.
24. Rosenne, E., Sorski, L., et al. In vivo suppression of NK cell cytotoxicity by stress and surgery: glucocorticoids have a minor role compared to catecholamines and prostaglandins. Brain Behav. Immun. 37 (2014), 207–219.
25. Shakhar, G., Ben-Eliyahu, S., In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J. Immunol. 160:7 (1998), 3251–3258.
26. Shakhar, G., Ben-Eliyahu, S., Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients?. Ann. Surg. Oncol. 10:8 (2003), 972–992.
27. Shakhar, G., Blumenfeld, B., Glucocorticoid involvement in suppression of NK activity following surgery in rats. J. Neuroimmunol. 138:1–2 (2003), 83–91.
28. Siegel, R.L., Miller, K.D., et al. Cancer statistics, 2015. CA Cancer J. Clin. 65:1 (2015), 5–29.
29. Sorski, L., Levi, B., et al. The impact of surgical extent and sex on the hepatic metastasis of colon cancer. Surg. Today 44:10 (2014), 1925–1934.
30. Sorski, L., Melamed, R., Lavon, H., Matzner, P., Rosenne, E., Ben-Eliyahu, S., Acute and innocuous CpG-C immune stimulation potentiates host resistance to hepatic metastases of colon cancer and protects against immunosuppressive effects of surgery. PNIRS Annual Scientific Meeting. Seattle, 2015.
31. Srivastava, S., Lundqvist, A., et al. Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy 10:8 (2008), 775–783.
32. Stolina, M., Sharma, S., et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164:1 (2000), 361–370.
33. Terunuma, H., Deng, X., et al. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int. Rev. Immunol. 27:3 (2008), 93–110.
34. Torgersen, K.M., Vaage, J.T., et al. Selective activation of cAMP-dependent protein kinase type I inhibits rat natural killer cell cytotoxicity. J. Biol. Chem. 272:9 (1997), 5495–5500.
35. Watkins, J.L., Thaker, P.H., et al. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer 121:19 (2015), 3444–3451.
36. Weitz, J., Herfarth, C., Surgical strategies and minimal residual disease detection. Semin. Surg. Oncol. 20:4 (2001), 329–333.
37. Whalen, M.M., Bankhurst, A.D., Effects of beta-adrenergic receptor activation, cholera toxin and forskolin on human natural killer cell function. Biochem. J. 272:2 (1990), 327–331.
38. Yakar, I., Melamed, R., et al. Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Ann. Surg. Oncol. 10:4 (2003), 469–479.
39. Yamaguchi, K., Takagi, Y., et al. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann. Surg. 232:1 (2000), 58–65.
40. Zmora, O., Shaashua, L., The perioperative use of a beta-adrenergic blocker and a COX-2 inhibitor in colorectal cancer patients for the prevention of cancer recurrence. A preliminary study assessing feasibility and safety. 23rd Annual PNIRS Scientific Meeting, Brighton, UK, BBI, 2016.